PIKFYVE and melanoma: Importantly, in a study of patients with melanoma treated with ICB49, pre-treatment expression of PIKFYVE in conventional DCs (cDC) was lower in responders (R) when compared to non-responders (NR) (Fig. 1f, g).There were no differences in PIKFYVE expression in any other immune cell type.